Csl
CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health. The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
DitchCarbon Score
How does Csl's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Csl's score of 29 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Csl's reported carbon emissions
In 2023, CSL Limited reported total carbon emissions of approximately 336,000,000 kg CO2e, comprising 113,000,000 kg CO2e from Scope 1 and 223,000,000 kg CO2e from Scope 2 emissions. The company has also disclosed significant Scope 3 emissions, amounting to about 2,284,000,000 kg CO2e in previous years. CSL has demonstrated a commitment to reducing its carbon footprint, with a focus on near-term targets, although it has not yet committed to a net-zero target. The company is actively working on initiatives to lower its emissions, particularly in the pharmaceuticals, biotechnology, and life sciences sector. Over the years, CSL has shown a trend of decreasing emissions intensity, with a reported Scope 1 and 2 GHG intensity of 0.02524417731029301 kg CO2e per USD of revenue in 2023. This reflects the company's ongoing efforts to enhance sustainability and reduce its environmental impact. CSL's headquarters is located in Australia, and it continues to align its operations with industry standards for climate action, demonstrating a proactive approach to addressing climate change challenges.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Csl is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
